Article

Stage IV DLK prognosis excellent with new approach to therapy

Loma Linda, CA-Recovery of full visual function is possible in eyes with stage IV diffuse lamellar keratitis (DLK) using a novel management paradigm that is based on a new pathophysiologic model of the disorder, said Brian R. Will, MD, assistant clinical professor of ophthalmology, Loma Linda University School of Medicine, Loma Linda, CA.

The clinical manifestations of stage IV DLK, including the flap macrostriae, stromal opacity, and hyperopic shift, are the result of focal flap and anterior stromal edema secondary to keratocyte dysfunction rather than a consequence of necrotic tissue loss, Dr. Will proposed. He described a management technique that is directed first at eliminating the edema followed later by flap lifting and stretching to eliminate the macrostriae. Finally, laser enhancement is performed as needed to correct any residual refractive error.

Use of that protocol in a consecutive series of eight eyes of six patients with stage IV DLK after all-laser LASIK (IntraLASIK) resulted in a final visual acuity outcome of 20/20 or better in all cases, reported Dr. Will, who is also medical director, Will Vision and Laser Centers, Vancouver, WA.

Even before the enhancement, all eyes had excellent uncorrected visual acuity (UCVA), and at the last available follow-up, UCVA and BCVA were 20/20 or better in all eyes. No eyes experienced any loss of BCVA, and no patients complained of problems with glare, halos, or other unwanted visual effects at the conclusion of therapy.

Keratocyte dysfunction

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.